Skip to main content

Table 3 Access to health services and opioid agonist treatment

From: Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada

Overall sample

N = 227

 

n (%)

Perceived access to health clinics

 

Harder

119 (52.4)

Easier

10 (4.4)

Same as usual

42 (18.5)

Don’t know

55 (24.2)

Perceived access to emergency departments

 

Harder

95 (41.9)

Easier

6 (2.6)

Same as usual

44 (19.4)

Don’t know

81 (35.7)

Perceived access to other hospital services

 

Harder

94 (41.4)

Easier

3 (1.3)

Same as usual

35 (15.4)

Don’t know

93 (41.0)

Perceived access to mental health services

 

Harder

82 (36.1)

Easier

2 (0.9)

Same as usual

34 (15.0)

Don’t know

106 (46.7)

OAT recipients

N = 69

 

n (%)

Discussed ≥ 1 strategy to favour OAT continuity with prescriber

33 (47.8)

Strategies discusseda:

 

Initiation of take-home/carry doses

15 (45.5)

Allowing longer take-home and prescription intervals

17 (51.5)

Arrangements to have medication delivered

9 (27.2)

Initiation of suboxone, methadone or other forms of treatment for opioid use disorder

7 (21.2)

Dosage modification

6 (18.2)

Initiation of co-medication (e.g. clonidine, loperamide)

2 (6.1)

Missed ≥ 1 OAT dose due to service disruptions

15 (21.7)

  1. OAT, opioid agonist treatment
  2. a% calculated among people reporting at least one strategy (n = 33)